Biogaia
BioGaia AB, commonly referred to as BioGaia, is a leading biotechnology company headquartered in Sweden. Founded in 1990, the company has established itself as a pioneer in the development of probiotic products, focusing on gut health and overall well-being. With a strong presence in Europe, North America, and Asia, BioGaia operates within the health and wellness industry, specifically in the probiotics sector. The company’s core offerings include a range of probiotic supplements and functional foods, distinguished by their unique strains of Lactobacillus reuteri. BioGaia's commitment to scientific research and innovation has led to numerous key milestones, including partnerships with major global brands and a robust portfolio of clinical studies supporting their products. Recognised for its market leadership, BioGaia continues to enhance its reputation through ongoing advancements in probiotic technology and consumer education.
DitchCarbon Score
How does Biogaia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biogaia's score of 59 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biogaia's reported carbon emissions
In 2024, BioGaia AB reported total greenhouse gas emissions of approximately 7,300,000 kg CO2e from Scope 3, 73,000 kg CO2e from Scope 1, and 33,000 kg CO2e from Scope 2. This reflects a slight increase in Scope 1 emissions from 77,000 kg CO2e in 2023, while Scope 2 emissions decreased from 32,000 kg CO2e in the same year. The company has set ambitious targets to reduce its Scope 1 and Scope 2 emissions by 46% by 2030, using 2019 levels as a baseline. This target has been validated by the Science Based Targets initiative (SBTi) and is aligned with the goal of limiting global warming to 1.5°C. BioGaia's long-term commitment includes striving for near-zero emissions in both Scope 1 and Scope 2 by 2050. The company is also focused on measuring and reducing its Scope 3 emissions, which accounted for the majority of its emissions in 2024. The emissions data is sourced directly from BioGaia AB (publ) and reflects their ongoing efforts to enhance sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 7,000 | 00,000 | - | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 61,000 | 00,000 | 00,000 | 0,000 | 00,000 | 00,000 | 00,000 |
| Scope 3 | 2,438,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biogaia is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
